Spotlight Therapeutics

Brief Description

Developer of next-generation gene editing therapeutics in a preclinical pipeline. The company creates programmable nucleases that selectively target and edit specific cell populations directly in the body. These engineered nucleases will enable direct intervention in vivo like a true administered biologic.

Inventor

Tech Category

  • Medical Therapeutics

JOIN OUR MAILING LIST

 

 
 
 
 

IPIRA is committed to meeting the needs of people with disabilities in a timely manner by preventing and removing barriers to accessibility. We also adhere to the UC Berkeley policy on nondiscrimination, and protect the privacy of confidential information.